Structure Therapeutics Inc. Sponsored ADR $GPCR Position Reduced by Casdin Capital LLC

Casdin Capital LLC lessened its stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 24.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,175,000 shares of the company’s stock after selling 380,000 shares during the period. Structure Therapeutics comprises approximately 5.1% of Casdin Capital LLC’s investment portfolio, making the stock its 6th largest holding. Casdin Capital LLC’s holdings in Structure Therapeutics were worth $81,721,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. CWM LLC boosted its position in Structure Therapeutics by 35.2% in the 4th quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 125 shares in the last quarter. HighTower Advisors LLC boosted its position in Structure Therapeutics by 3.6% in the 4th quarter. HighTower Advisors LLC now owns 9,320 shares of the company’s stock worth $648,000 after purchasing an additional 320 shares in the last quarter. State of Wyoming boosted its position in Structure Therapeutics by 29.7% in the 4th quarter. State of Wyoming now owns 1,761 shares of the company’s stock worth $122,000 after purchasing an additional 403 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Structure Therapeutics by 9.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 4,828 shares of the company’s stock worth $135,000 after purchasing an additional 413 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in Structure Therapeutics by 4.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,888 shares of the company’s stock worth $757,000 after purchasing an additional 444 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Stock Performance

Shares of GPCR stock opened at $45.00 on Thursday. The stock’s fifty day moving average is $43.09 and its two-hundred day moving average is $57.53. The firm has a market capitalization of $3.20 billion, a P/E ratio of -51.72 and a beta of -1.35. Structure Therapeutics Inc. Sponsored ADR has a fifty-two week low of $15.80 and a fifty-two week high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. On average, equities analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Citizens Jmp lowered their price objective on Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a research report on Friday, February 27th. William Blair restated an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. Wolfe Research assumed coverage on Structure Therapeutics in a research report on Thursday, March 26th. They issued a “peer perform” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Tuesday, April 21st. Finally, Leerink Partners restated an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $106.75.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.